BioMarin Pharmaceutical Inc · Q3 2022 earnings

Briefing

BioMarin reported a 24% year-over-year total revenue growth (31% excluding KUVAN) and VOXZOGO contributed $48 million, leading to increased full-year guidance.

BioMarin announced strong Q3 2022 results, with a 24% increase in total revenue compared to the same period in 2021. VOXZOGO's performance was a key driver, leading to an increased full-year net product revenue guidance. The company also highlighted the European regulatory approval and commercial launch of ROCTAVIAN, as well as the acceptance of the U.S. Biologics Application for ROCTAVIAN by the FDA.

• Total revenues increased by 24% year-over-year, reaching $505.3 million.
• VOXZOGO contributed $48 million to revenue, leading to an increased full-year net product revenue guidance of $140 to $170 million.
• The U.S. Biologics Application for ROCTAVIAN was accepted by the FDA with a PDUFA target action date of March 31, 2023.
• Commercial launch of ROCTAVIAN is underway in the European Union following approval in August 2022.

Headline financials

Revenue & EPS history

BioMarin revised its full-year 2022 VOXZOGO net product revenue guidance to between $140 million and $170 million. Total Revenues, VIMIZIM Net Product Revenues, NAGLAZYME Net Product Revenues, PALYNZIQ Net Product Revenues, KUVAN Net Product Revenues, BRINEURA Net Product Revenues, Cost of Sales (% of Total Revenues), GAAP Net Income, and Non-GAAP Income guidance remained unchanged. Research and Development Expense was revised from $665 to $715 million to $650 to $700 million. Selling, General and Administrative Expense was revised from $790 to $840 million to $800 to $850 million.